Faisal Khurshid
Stock Analyst at Leerink Partners
(0.67)
# 3,684
Out of 4,814 analysts
19
Total ratings
28.57%
Success rate
-22.63%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IRWD Ironwood Pharmaceuticals | Maintains: Market Perform | $3 → $1 | $0.73 | +37.55% | 2 | Apr 14, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Outperform | $45 | $12.65 | +255.73% | 1 | Apr 8, 2025 | |
| NRIX Nurix Therapeutics | Initiates: Market Perform | $16 | $9.32 | +71.67% | 1 | Mar 17, 2025 | |
| STTK Shattuck Labs | Initiates: Outperform | $4 | $0.77 | +419.41% | 1 | Mar 17, 2025 | |
| PLRX Pliant Therapeutics | Downgrades: Market Perform | $33 → $2 | $1.46 | +36.99% | 2 | Mar 3, 2025 | |
| ATYR aTyr Pharma | Initiates: Outperform | $16 | $3.11 | +414.47% | 1 | Feb 18, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Outperform | $60 | $26.00 | +130.77% | 2 | Dec 27, 2024 | |
| ANIP ANI Pharmaceuticals | Initiates: Outperform | $80 | $69.30 | +15.44% | 1 | Dec 11, 2024 | |
| ZURA Zura Bio | Initiates: Outperform | $15 | $1.24 | +1,114.57% | 1 | Nov 4, 2024 | |
| TRVI Trevi Therapeutics | Assumes: Outperform | $7 | $6.09 | +14.94% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $16.74 | +168.76% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $24 | $24.72 | -2.89% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.27 | +453.36% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $4.54 | +76.41% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $5 | $0.98 | +412.77% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $2.79 | +294.97% | 1 | Mar 21, 2023 |
Ironwood Pharmaceuticals
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $0.73
Upside: +37.55%
Spyre Therapeutics
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $12.65
Upside: +255.73%
Nurix Therapeutics
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $9.32
Upside: +71.67%
Shattuck Labs
Mar 17, 2025
Initiates: Outperform
Price Target: $4
Current: $0.77
Upside: +419.41%
Pliant Therapeutics
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.46
Upside: +36.99%
aTyr Pharma
Feb 18, 2025
Initiates: Outperform
Price Target: $16
Current: $3.11
Upside: +414.47%
Kymera Therapeutics
Dec 27, 2024
Maintains: Outperform
Price Target: $60
Current: $26.00
Upside: +130.77%
ANI Pharmaceuticals
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $69.30
Upside: +15.44%
Zura Bio
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $1.24
Upside: +1,114.57%
Trevi Therapeutics
Sep 9, 2024
Assumes: Outperform
Price Target: $7
Current: $6.09
Upside: +14.94%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $16.74
Upside: +168.76%
Sep 9, 2024
Initiates: Market Perform
Price Target: $24
Current: $24.72
Upside: -2.89%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.27
Upside: +453.36%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $4.54
Upside: +76.41%
Sep 9, 2024
Assumes: Outperform
Price Target: $5
Current: $0.98
Upside: +412.77%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $2.79
Upside: +294.97%